Eli Lilly headquarters located in Indianapolis, Indiana.
The U.S. Food and Drug Administration found eight separate manufacturing problems at an Eli Lilly plant in Branchburg, N.J., during an inspection last summer. The inspection report, obtained by Reuters under a Freedom of Information Act request, cited problems in tracking manufacturing processes and quality controls; lapses in equipment calibration; and failure to properly maintain facilities and equipment.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
